[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"4827359c-749f-4084-aeb0-6c8f0ce2d993","acronym":"dendritic cell","url":"https://clinicaltrials.gov/study/NCT07479667","created_at":"2026-03-28T01:39:16.862Z","updated_at":"2026-03-28T01:39:16.862Z","phase":"Phase 1","brief_title":"An Antibody-armored Dendritic Cell in Patients With Solid Tumors","source_id_and_acronym":"NCT07479667 - dendritic cell","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" KRAS • TP53","pipe":"","alterations":" ","tags":["KRAS • TP53"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 02/05/2026","start_date":" 02/05/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2026-03-18"},{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"778d6e97-aaea-4385-b9ac-14c267296d2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474324","created_at":"2026-03-28T01:42:37.705Z","updated_at":"2026-03-28T01:42:37.705Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","source_id_and_acronym":"NCT07474324","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2026-03-16"},{"id":"d3f14d68-e312-4d2c-a67b-b4c533956873","acronym":"","url":"https://clinicaltrials.gov/study/NCT07183358","created_at":"2025-09-27T08:46:37.374Z","updated_at":"2025-09-27T08:46:37.374Z","phase":"","brief_title":"Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer","source_id_and_acronym":"NCT07183358","lead_sponsor":"The Affiliated Hospital of Qingdao University","biomarkers":" CLDN1","pipe":"","alterations":" ","tags":["CLDN1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/20/2025","start_date":" 09/20/2025","primary_txt":" Primary completion: 03/20/2026","primary_completion_date":" 03/20/2026","study_txt":" Completion: 06/20/2026","study_completion_date":" 06/20/2026","last_update_posted":"2025-09-19"},{"id":"87b594ce-090b-4f4f-8607-c4cad1156d5d","acronym":"SAH","url":"https://clinicaltrials.gov/study/NCT07180966","created_at":"2025-09-20T07:04:29.480Z","updated_at":"2025-09-20T07:04:29.480Z","phase":"","brief_title":"Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation","source_id_and_acronym":"NCT07180966 - SAH","lead_sponsor":"Ruijin Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 780","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-09-18"},{"id":"a3f2cdb8-5f51-4d49-bdd8-408b76b63c70","acronym":"ZANGEA","url":"https://clinicaltrials.gov/study/NCT07176312","created_at":"2025-09-20T07:08:39.876Z","updated_at":"2025-09-20T07:08:39.876Z","phase":"Phase 2","brief_title":"Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","source_id_and_acronym":"NCT07176312 - ZANGEA","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-09-16"},{"id":"8429aef2-3578-430a-8f3c-fc5f753d6982","acronym":"","url":"https://clinicaltrials.gov/study/NCT07161453","created_at":"2025-09-13T08:46:03.641Z","updated_at":"2025-09-13T08:46:03.641Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","source_id_and_acronym":"NCT07161453","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-08"},{"id":"efd9f946-f015-462e-a89d-d7d3988373c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07149181","created_at":"2025-08-30T13:47:49.395Z","updated_at":"2025-08-30T13:47:49.395Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery","source_id_and_acronym":"NCT07149181","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/31/2025","start_date":" 08/31/2025","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-08-29"},{"id":"40eafc96-e8a8-4405-abf1-3e7824637479","acronym":"","url":"https://clinicaltrials.gov/study/NCT07132528","created_at":"2025-08-23T13:29:17.809Z","updated_at":"2025-08-23T13:29:17.809Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","source_id_and_acronym":"NCT07132528","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/31/2025","start_date":" 08/31/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-08-20"},{"id":"7aa880e7-6b68-409d-ae45-4371e34c60af","acronym":"","url":"https://clinicaltrials.gov/study/NCT06979895","created_at":"2025-06-28T16:15:27.825Z","updated_at":"2025-06-28T16:15:27.825Z","phase":"","brief_title":"Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer","source_id_and_acronym":"NCT06979895","lead_sponsor":"Xijing Hospital","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/25/2025","start_date":" 05/25/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-05-20"},{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"38f6d35a-64a3-4650-878e-b5837dc695fe","acronym":"BLENTI","url":"https://clinicaltrials.gov/study/NCT06940778","created_at":"2025-09-07T01:21:55.747Z","updated_at":"2025-09-07T01:21:55.747Z","phase":"","brief_title":"LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS","source_id_and_acronym":"NCT06940778 - BLENTI","lead_sponsor":"Hospital do Coracao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 273","initiation":"Initiation: 01/10/2025","start_date":" 01/10/2025","primary_txt":" Primary completion: 06/10/2026","primary_completion_date":" 06/10/2026","study_txt":" Completion: 12/10/2026","study_completion_date":" 12/10/2026","last_update_posted":"2025-04-27"},{"id":"722a2a86-9fad-4d71-874a-87f0351a5eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06925243","created_at":"2025-06-28T16:10:56.066Z","updated_at":"2025-06-28T16:10:56.066Z","phase":"Phase 3","brief_title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06925243","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 682","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-22"},{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"4fc01b9a-9df5-4f53-8422-95df5487e1e6","acronym":"BUDDLE","url":"https://clinicaltrials.gov/study/NCT06858644","created_at":"2025-09-07T01:49:40.667Z","updated_at":"2025-09-07T01:49:40.667Z","phase":"","brief_title":"Development of a Predictive Model for Gastric Cancer Peritoneal Metastasis and Cachexia Using BUB1 and Radiopathomics Data With Deep Learning","source_id_and_acronym":"NCT06858644 - BUDDLE","lead_sponsor":"Qun Zhao","biomarkers":" BUB1","pipe":"","alterations":" ","tags":["BUB1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-03-05"},{"id":"0b405f7d-3f61-4823-b79f-2d25bdb0eeb2","acronym":"SGNPDL1V-001","url":"https://clinicaltrials.gov/study/NCT05208762","created_at":"2023-05-26T17:05:40.425Z","updated_at":"2025-02-25T13:49:21.100Z","phase":"Phase 1","brief_title":"A Study of SGN-PDL1V in Advanced Solid Tumors","source_id_and_acronym":"NCT05208762 - SGNPDL1V-001","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PF-08046054"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 11/18/2027","primary_completion_date":" 11/18/2027","study_txt":" Completion: 11/17/2028","study_completion_date":" 11/17/2028","last_update_posted":"2025-02-21"},{"id":"488850a4-401a-418b-88e8-32f7b6c5f0dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038578","created_at":"2023-09-15T18:09:55.230Z","updated_at":"2025-02-25T13:41:43.311Z","phase":"Phase 2","brief_title":"A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer","source_id_and_acronym":"NCT06038578","lead_sponsor":"Toray Industries, Inc","biomarkers":" CAPRIN1","pipe":"","alterations":" ","tags":["CAPRIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • TRK-950"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-21"},{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"6d7c8fa9-67d2-4bc9-bef1-9bdadb373194","acronym":"","url":"https://clinicaltrials.gov/study/NCT04863430","created_at":"2021-04-28T12:52:46.950Z","updated_at":"2025-02-25T13:49:08.094Z","phase":"Phase 2","brief_title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","source_id_and_acronym":"NCT04863430","lead_sponsor":"Peking University","biomarkers":" HER-2 • GPC3 • SALL4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • GPC3 • SALL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 07/06/2023","primary_completion_date":" 07/06/2023","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2025-02-21"},{"id":"d0e8c003-1353-4bf0-ae65-13236586de27","acronym":"AIM-NIVO","url":"https://clinicaltrials.gov/study/NCT03816345","created_at":"2021-01-18T18:51:20.043Z","updated_at":"2025-02-25T13:39:45.299Z","phase":"Phase 1","brief_title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","source_id_and_acronym":"NCT03816345 - AIM-NIVO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • IL2","pipe":"","alterations":" ","tags":["MSI • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"dc06b6ac-0a69-4fa1-bf0d-291d63c5c2bc","acronym":"HERTHENA-PanTumor01","url":"https://clinicaltrials.gov/study/NCT06172478","created_at":"2023-12-15T19:20:07.848Z","updated_at":"2025-02-25T13:41:58.738Z","phase":"Phase 2","brief_title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06172478 - HERTHENA-PanTumor01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ERBB3","pipe":"","alterations":" ","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 02/26/2024","start_date":" 02/26/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"a744dd9f-e4be-4b72-a2de-da79e8056978","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800964","created_at":"2023-04-06T14:03:12.774Z","updated_at":"2025-02-25T13:55:05.180Z","phase":"Phase 1","brief_title":"Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05800964","lead_sponsor":"Amgen","biomarkers":" MSLN • CDH3","pipe":"","alterations":" ","tags":["MSLN • CDH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 305"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 06/10/2027","primary_completion_date":" 06/10/2027","study_txt":" Completion: 02/12/2028","study_completion_date":" 02/12/2028","last_update_posted":"2025-02-20"}]